Kohei Shitara, Medical Oncologist at National Cancer Center Hospital East, shared a post on X:
“Thrilled to share phase 3 HERIZON-GEA-01 in NEJM before ASCO 2026.
Biparatopic anti-HER2 Zanidatamab plus chemo±tislelizumab improved PFS in HER2+ gastric/GEJ cancer; the tislelizumab combo also improved OS. Grateful to all patients and collaborators.”
Title: Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
Authors: Kohei Shitara, Elena Elimova, Tianshu Liu, Josep Tabernero, Keun-Wook Lee, Michael Schenker, Niall C. Tebbutt, Jaffer Ajani, Norhidayu Salimin, Geoffrey Ku, Jong Gwang Kim, Inmaculada Ales Diaz, Jingdong Zhang, Filippo Pietrantonio, Li-Yuan Bai, Samuel Le Sourd, Jun Zhao, Cinta Hierro, Andrew Kiberu, Filip Van Herpe, Yuanyuan Bao, Hanze Zhang, Lin Yang, Vincent Li, Elaina M. Gartner, Ye Chen, Jonathan Grim, Sun Young Rha, Lin Shen for the HERIZON-GEA-01 Investigators
Other articles featuring Kohei Shitara on OncoDaily.